Facilities & Capacity

Sanofi to cut hundreds of jobs at two India vaccine plants

Sanofi plans to let go of all its employees at its manufacturing facilities near Hyderbad, following an operations review. According to Reuters, the decision for French drug maker Sanofi to let go of all employees at its two Indian vaccine plants follows the firm’s failure to win a UNICEF contract. The article outlined around 800 members of staff could be affected by the decision and said the Sanofi sources are not being named due to confidentiality. Sanofi did not respond…

Kaneka injects $15m to expand mRNA capacity in Belgium

Kaneka Eurogentec says the investment will create a production capacity approximately five times higher than at its plant in Liège, Belgium. Contract development manufacturing organization (CDMO) Kaneka Eurogentec, an affiliate of Kaneka Corporation, provides offerings including plasmid DNA (pDNA), recombinant proteins, and oligonucleotide services. In 2020, the company started production services for messenger RNA (mRNA) and the $15 million investment aims to scale-up capacity and expand its CDMO business with operations expected to begin from the end of this year. According…

Biomanufacturing Lotte! CDMO to invest $3bn in Korea

Lotte will invest $3 billion over the next seven years to construct three ‘mega’ plants in Korea with a production capacity of 360,000 L. Contract development manufacturing organization (CDMO) Lotte Biologics said each plant will have the ability to produce 120,000 L of antibody drugs. Furthermore, the plants will have additional expansion plans to include a small-scale incubator for clinical drug substance manufacture and a commercial drug product production facility. The build-out of its first plant will start in the…

Resilience steps out of North America to build UAE facility

Resilience has signed a deal with its investor Mubadala Investment Company PJSC to establish a secure supply chain and will construct a facility in Abu Dhabi, UAE. Under the terms of the deal, Abu Dhabi sovereign investment firm Mubadala will be responsible for the build-out of the manufacturing facility. However, the plant will be operated by National Resilience to produce specific biopharmaceutical-related products in the United Arab Emirates (UAE). “As many other governments across the globe, Mubadala has recognized the…

Argonaut to expand fill/finish capabilities in California

CMO Argonaut Manufacturing Services will use capital investment led by Telegraph Hill Partners to expand its manufacturing capabilities in Carlsbad, California. Contract manufacturing organization (CMO) Argonaut serves the life sciences, biopharma, and molecular diagnostics space. While specific financial details have not been disclosed, the firm said the investment will be focused on expanding its Carlsbad manufacturing facilities by installing a fill/finish line. According to Argonaut, the addition of a fill/finish line will expand the CMO’s footprint on the west coast…

2023 is the year for plug-in manufacturing, says BioNTech

BioNTech will make the first mRNA vaccines in Africa this year using its plug-in manufacturing tech, the firm told JP Morgan Conference delegates. Last week, CEO of BioNTech Ugur Sahin described to JPM delegates how the learnings of the pandemic highlighted that “poor countries didn’t get vaccines doses.” However, Sahin offered up a solution to this, saying “the only way to change that is to implement manufacturing technology.” In particular, he drew upon the company’s activity in Rwanda, Africa but…

Swissmedic licenses expanded KBI mammalian cell manufacturing plant

KBI Biopharma says Swissmedic licensure for its expanded mammalian cell manufacturing facility in Geneva will be key to helping customers optimize processes and cut costs. The contract development and manufacturing organization (CDMO) was licensed in December after the Swiss drug regulator deemed KBI’s mammalian cell manufacturing plant was in compliance with current Good Manufacturing Practice (cGMP) standards. Chief operating officer Mike Landau said the licensure allows KBI to fully support clients in their next phases of growth and certifies the…

Recipharm warns of fill/finish competition as COVID-19 vax demand dwindles

There is significant market demand for global sterile capacity says Recipharm. But as the need for COVID-19 vaccine filling decreases, competition between CDMOs will rise. Swedish contract development manufacturing organization (CDMO) Recipharm has made various investments across the globe to strengthen its fill-finish capabilities and capacity. In October, the firm scaled up its sterile filling capabilities by investing in Lab+ technology used for low volume blow-fill-seal (BFS) filling at its plant in Kaysersberg, France. Furthermore, the CDMO signed a Memorandum…

Catalent to inject $40m to expand biologics services in NC

Catalent says it will invest up to $40 million to fit its 80,000 square-foot Durham, North Caroline facility with automation and digitization capabilities. Contract development manufacturing organization (CDMO) Catalent will establish a biologics analytical center in North Carolina’s Research Triangle (RTP) to provide its clients with standalone testing for biologic drug modalities, cell and gene therapies, and analytical development. “The new Durham facility, which was already purpose-built as laboratory space, will first need to be fitted out to meet the…

Cell Therapy — Supply Chain Discussions

The 2017 approval of Kymriah (tisagenlecleucel) has paved the way for other cell therapy products to reach the patients who need them. Each passing year promises to open the regulatory floodgates to more product approvals, but technical and manufacturing issues continue to keep initially high expectations from being realized. One barrier is supply chain complexity, especially for the subset of autologous cell therapies. This eBook features expert commentary from Be The Match BioTherapies, a company providing more than 50 product…